Stay updated on Safety of WVE-210201 in Duchenne Muscular Dystrophy Clinical Trial
Sign up to get notified when there's something new on the Safety of WVE-210201 in Duchenne Muscular Dystrophy Clinical Trial page.

Latest updates to the Safety of WVE-210201 in Duchenne Muscular Dystrophy Clinical Trial page
- Check5 days agoChange DetectedNew study locations added: Georgia (USA) and Ontario (Canada). The page revision was updated to v3.3.3.SummaryDifference0.3%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedThe government funding status notice was removed from the page; all study details and links remain unchanged.SummaryDifference0.4%

- Check55 days agoChange DetectedThe two screenshots show the same study record with only layout tweaks and no modification to essential study details like inclusion criteria or primary outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference5%

- Check90 days agoChange DetectedUpdate to version v3.1.0 with removal of several health topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the page.SummaryDifference0.8%

Stay in the know with updates to Safety of WVE-210201 in Duchenne Muscular Dystrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of WVE-210201 in Duchenne Muscular Dystrophy Clinical Trial page.